Registry Study on Drug Therapy and Clinical Outcomes in Patients With Acute Coronary Syndrome

Acute Coronary Syndrome Clinical Trial

Official title:

Registry Study on Drug Therapy and Clinical Outcomes in Patients With Acute Coronary Syndrome

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT04184583
• Other study ID #: ANZHEN HOSPITOL-LY-02
• Status: Not yet recruiting
• Start date: December 2019
• Est. completion date: December 2026

Study information

• Verified date: November 2019
• Source: Beijing Anzhen Hospital
• Contact: Yi Zhang, PhD
• Phone: 86-010-64456609
• Email: phd-zhangyi[@]outlook.com
• Is FDA regulated: No
• Study type: Observational [Patient Registry]

Clinical Trial Summary

Registry Study on Drug Therapy and Clinical Outcomes in Patients With Acute Coronary Syndrome

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 10000
• Est. completion date: December 2026
• Est. primary completion date: December 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Informed consent has been signed.

• Patients diagnosed in our hospital with acute coronary syndrome.

• Age =18.

• Life expectancy =12 months.

Exclusion Criteria:

• Severe lack of important information such as history of previous medication, history of previous disease, history of surgery.

• Pregnant and lactating women.

• Mental disorders, or inability to communicate effectively with researchers, or failure to comply with research protocols.

Related Conditions & MeSH terms

• Acute Coronary Syndrome
• Drug Therapy
• Syndrome

Locations

Country	Name	City	State
China	Beijing Anzhen Hospital	Beijing	Beijing

Sponsors (1)

Lead Sponsor	Collaborator
Beijing Anzhen Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	main adverse cardiovascular and cerebrovascular events (MACCE)	MACCE will be defined as all-cause death, non-fatal stroke, non-fatal myocardial infarction (MI), and ischemic-driven revascularization.	up to 5 years
Secondary	Adverse drug reaction	Adverse drug reaction will be defined as any adverse reactions in the patients.	up to 5 years